Screening for pancreatic cancer in high-risk individuals
Pancreatic Cancer Screening in a Population at High Risk
This study is testing different ways to screen people at high risk for pancreatic cancer to see if early detection can help them live longer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 700 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Masaryk Memorial Cancer Institute Academic / other |
| Locations | 1 site (Brno) |
| Trial ID | NCT06330441 on ClinicalTrials.gov |
What this trial studies
This study focuses on screening individuals at high risk for pancreatic ductal adenocarcinoma, particularly those with hereditary conditions or chronic pancreatic diseases. It employs interventions such as endoscopic ultrasonography, magnetic resonance imaging, and laboratory examinations to detect the disease early. The aim is to improve early diagnosis and potentially increase survival rates by identifying the disease before it becomes advanced. The study is conducted in the Czech Republic, where the incidence of pancreatic cancer is rising.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 18 and older with chronic pancreatic diseases or confirmed hereditary syndromes associated with increased pancreatic cancer risk.
Not a fit: Patients without a family history of pancreatic cancer or those not meeting the specific high-risk criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection of pancreatic cancer in high-risk patients, improving treatment outcomes and survival rates.
How similar studies have performed: Other studies have shown promise in early detection of pancreatic cancer through targeted screening in high-risk populations, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * willing to participate in the study * age 18+ * arms specific criteria: A: * chronic pancreatic disease in the context of cystic fibrosis or chronic pancreatitis * age 50+ B1: * confirmed Peutz-Jegherson syndrome (mutSTK11) + age over 35 years or 10 years earlier than pancreatic ductal adenocarcinoma was diagnosed in the youngest family member * familial melanoma syndrome (mutCDKN2A) + age over 40 years or 10 years before pancreatic ductal adenocarcinoma was diagnosed in the youngest family member * confirmed hereditary pancreatitis (mutPRSS1) + age over 40 years or 20 years after the first attack B2: * confirmed diagnosis of hereditary syndrome (Lynch syndrome /mutMLH1, mutMSH2, mutMSH6, mutPMS2, mutEPCAM/, HBOC /mutBRCA1, mutBRCA2, mutPALB2, mutATM/, familial adenomatous polyposis /mutAPC/, Li-Fraumeni syndrome /mutTP53/) * at least one relative with a diagnosis of pancreatic ductal adenocarcinoma in family anamnesis at the same time (Grade I or II relative) * age over 50 years, or 10 years before the pancreatic ductal adenocarcinoma was diagnosed in the youngest relative - which comes first C: * positive family anamnesis of pancreatic ductal adenocarcinoma without hereditary syndrome context * age 50+ or 10 years earlier than the youngest relative with pancreatic ductal adenocarcinoma - screening is recommended for all first-degree relatives of affected family members Exclusion Criteria: * Inability to undergo radical curative surgery for a pancreatic tumor. * Inability to undergo scheduled imaging examinations. * Incurable malignant cancer.
Where this trial is running
Brno
- Masaryk Memorial Cancer Institute — Brno, Czechia (Recruiting)
Study contacts
- Study coordinator: Martina Lojova, Ph.D.
- Email: martina.lojova@mou.cz
- Phone: +420543136232
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.